Clinical Trial: Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157787) titled 'Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)' on Aug. 28.

Brief Summary: The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

Study Start Date: Oct. 17

Study Type: INTERVENTIONAL

Condition: Primary Membranous Nephropathy

Intervention: DRUG: ALXN1920

Participants will receive ALXN1920 SC infusion.

DRUG: Placebo

Participants will receive Placebo SC infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Alexion Pharmac...